ofatumumab

Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Biopharma Dive
Novartis
FDA
Kesimpta
ofatumumab
MS
multiple sclerosis
Flag link:
FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug
FDA Delays Ruling on Novartis’ Relapsing Multiple Sclerosis Drug
BioSpace
Novartis
Arzerra
FDA
ofatumumab
relapsing multiple sclerosis
Flag link:
Novartis builds case for MS drug ofatumumab as FDA decision looms
Novartis builds case for MS drug ofatumumab as FDA decision looms
Pharmaforum
Novartis
ofatumumab
clinical trials
MS
multiple sclerosis
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Novartis’ ofatumumab meets primary endpoints in two phase 3 RMS trials
Pharmaceutical Business Review
Novartis
ofatumumab
OMB157
Aubagio
clinical trials
relapsing multiple sclerosis
Flag link:
Novartis takes aim at Roche's star MS drug
Novartis takes aim at Roche's star MS drug
Reuters
Novartis
Roche
multiple sclerosis
Arzerra
ofatumumab
Ocrevus
Flag link:
Upcoming events – Phase III data for Chiasma and Novartis
Upcoming events – Phase III data for Chiasma and Novartis
EP Vantage
Chiasma
acromegaly
Mycapssa
clinical trials
multiple sclerosis
Novartis
ofatumumab
Flag link:
GlaxoSmithKline flips an MS project to Novartis for up to $1B
GlaxoSmithKline flips an MS project to Novartis for up to $1B
Fierce Biotech
GSK
Novartis
MS
multiple sclerosis
ofatumumab
Flag link:
Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint
Glaxo, Genmab report phase III ofatumumab study did not meet primary endpoint
The Fly on the Wall
GSK
Genmab
ofatumumab
large B-cell lymphoma
Flag link:
Genmab announces positive results for sclerosis drug candidate
Genmab announces positive results for sclerosis drug candidate
Reuters
Genmab
MS
multiple sclerosis
ofatumumab
Flag link:
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Yahoo/Globe Newswire
ofatumumab
GSK
Genmab
Arzerra
leukemia
chronic lymphocytic leukemia
Flag link:
GlaxoSmithKline amends deal with Genmab
GlaxoSmithKline amends deal with Genmab
Yahoo/AP
GSK
Genmab
partnerships
ofatumumab
Flag link: